Mesothelioma Cancer Centers
Smilow Cancer Hospital at Yale-New Haven
Doctors Affiliated with this Treatment Facility
Yale-New Haven Hospital's history dates back to 1826, when the General Hospital Society of Connecticut was founded as the first hospital in the state. The hospital rented a building until 1833, when a new 13-bed facility named State Hospital was built. During the Civil War, State Hospital was used as a military hospital to care for wounded Union soldiers, but it returned to treating the public after the war. Over the years, New Haven residents began informally referring to the hospital as "New Haven Hospital," and in 1884 the name was officially adopted. New Haven Hospital formalized its relationship with the Yale School of Medicine in 1913, although it would not become Yale-New Haven Hospital until the mid-1960s. Decades later, Smilow Cancer Hospital opened its doors in October 2009.
Smilow Cancer Hospital at Yale New Haven Hospital’s Thoracic Oncology Program provides multidisciplinary treatment for those diagnosed with mesothelioma and other lung cancers. Their advanced research gives patients personalized targeted thoracic therapy throughout their treatment, whether it is in its early stages or advanced. The hospital is considered a leader in thoracic and lung malignancies, providing personalized care to all patients and help leading research efforts for a number of cancers.
Specialists in the Thoracic Oncology Program meet on a regular basis to discuss specific patient treatment issues and develop a plan and personalized options. Their collective expertise in medical and radiation oncology, pulmonary medicine and thoracic surgery provide patients with options and cutting-edge treatments such as 4D conformal treatment planning and minimally invasive surgery. The program at Smilow Cancer Hospital also offers access to clinical trials at their location, as well as through their partnership with Yale Cancer Center, providing patients with a range of promising treatment options. Their partner, Yale Cancer Center, is a National Cancer Institute (NCI) designated comprehensive cancer center as they help lead cancer research to help improve prevention, as well as develop new diagnostic tools and treatments. In particular, the research centers are investigating ways to lower risk of cancer and screening for lung cancer and molecular characterization of lung cancers. The Thoracic Oncology Program fosters collaborations among those actively treating patients and those focused on research to ensure patients always get the latest and best treatments possible.
Smilow Cancer Hospital provides support options for patients and their families, including art programs, cancer support groups, spiritual care and survivorship clinics. They also provide an integrative medicine program for patients which focuses on physical and emotional hardships during treatment, ultimately establishing a relationship between the patient and practitioner to achieve health and healing.
- Diagnostic imaging
- Medical oncology
- Pulmonary medicine
- Radiation oncology
- Thoracic surgery
- National Best Hospitals by U.S. News & World Report
- Magnet designation from the American Nurses Credentialing Center (ANCC)
Mesothelioma Clinical Trials at Smilow Cancer Hospital at Yale-New Haven
The following clinical trials are in progress or actively recruiting participants at Smilow Cancer Hospital at Yale-New Haven:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: July 18, 2019 Status: Recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma Last Updated: January 16, 2019 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette